• Corpus ID: 58719270

The $1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine

@inproceedings{Davies2010TheG,
  title={The \$1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine},
  author={Kevin Davies},
  year={2010}
}
In 2000, President Bill Clinton signaled the completion of the Human Genome Project at a cost in excess of $2 billion. A decade later, the price for any of us to order our own personal genome sequence--a comprehensive map of the 3 billion letters in our DNA--is rapidly and inevitably dropping to just $1,000. Dozens of men and women--scientists, entrepreneurs, celebrities, and patients--have already been sequenced, pioneers in a bold new era of personalized genomic medicine. The $1,000 genome… 
Pathologists and the third wave of medical genomics.
TLDR
Over the past two decades, notions about how genome science and technology would improve health and healthcare have changed, and only a handful of genome-derived drugs have reached the market to date.
Basic Principles of Human Genetics : A Primer for Oral Medicine
TLDR
Increasingly, a growing and evolving body of knowledge and information has significantly expanded how the authors think about and how they use human genetics in medicine and dentistry to address epidemiology, public health and risk assessment, single and multiple predictive and prognostic gene-based diagnostics, and pharmacogenomics and Pharmacogenetics with customized drug selection specific for individualized metabolism.
The Genome Doctor, a Whole-Genome Sequencing Approach to Cancer
TLDR
The challenges and potential in the clinical application of whole-genome sequencing for cancer are addressed and the merits of such large-scale, expensive, time-consuming, dataharvesting, and descriptive approaches are questioned.
More than Moore’s Mores: Computers, Genomics, and the Embrace of Innovation
TLDR
By delving into the history of speculative thinking about sequencing and computing, this article demonstrates just how much more receptive to high-risk/high-payoff ventures the NIH and the general public have become.
Dr. Sanger, meet Mr. Moore
  • Hallam Stevens
  • Biology
    BioEssays : news and reviews in molecular, cellular and developmental biology
  • 2012
TLDR
This Commentary is an attempt to begin a discussion about what the effects of nextgeneration might be and to understand some of the origins and history of Moore’s Law.
From Phenotype to Genotype
  • H. Slavkin
  • Medicine, Biology
    Journal of dental research
  • 2014
TLDR
The authors are now at the beginning of a new era using human and microbial whole-genome sequencing to make significant healthcare decisions as to risk, stratification of patients, diagnosis, treatments, and outcomes.
Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor
TLDR
It is predicted that TCGA landmarks may prove far more useful for cancer prevention than for cancer diagnosis and treatment when considering the effect of non-cancer genes and the normal genetic background on tumor microenvironment.
Critical appraisal of the private genetic and pharmacogenomic testing environment in Greece.
TLDR
Molecular genetic and cytogenetic testing were found to be the predominant types of genetic testing services offered although there is an increasing demand for pharmacogenomic testing.
...
...